• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Clinical trials moving to emerging countries

News
Article

International pharmaceutical companies are increasingly out-sourcing clinical trials to countries in Asia, Latin America, and Eastern Europe, in an attempt to save time, money, and resources, according to a new report from GBI Research.

International pharmaceutical companies are increasingly out-sourcing clinical trials to countries in Asia, Latin America, and Eastern Europe, in an attempt to save time, money, and resources, according to a new report from GBI Research.

The study notes that every drug that fails to make it through clinical testing represents a financial loss. So with squeezed Research and Development budgets, pharmaceutical companies are entering into risk-sharing agreements with Contract Research Organizations (CROs) in emerging nations for the management of clinical trials.

Drug discovery companies such as Advinus, WuXi AppTec, and Aurigene have all delivered their targets ahead of schedule and helped the big pharmaceutical companies to accelerate their drug research at considerably lower costs.

As more pharmaceutical companies have taken advantage of CROs, the total number of clinical trials conducted in the United States has fallen from 60% of the global sum in 2002 to 40% in 2010, the report says. In 2010, Europe carried out 25% of all clinical trials, while East Asia accounted for 10%. Canada, the Middle East, South America, and India followed with 6.1%, 4%, 3%, and 2.5%, respectively.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.